Verici Dx (Verici Dx) Debt-to-Asset : 0.07 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Debt-to-Asset?

Verici Dx's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.16 Mil. Verici Dx's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.46 Mil. Verici Dx's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2023 was $9.35 Mil. Verici Dx's debt to asset for the quarter that ended in Jun. 2023 was 0.07.

Verici Dx Debt-to-Asset Historical Data

The historical data trend for Verici Dx's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Debt-to-Asset Chart

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

Debt-to-Asset

0.05

Verici Dx Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23
Debt-to-Asset	-	-	-	0.05	0.07

Competitive Comparison of Verici Dx's Debt-to-Asset

For the Diagnostics & Research subindustry, Verici Dx's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verici Dx's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Verici Dx's Debt-to-Asset falls into.

Verici Dx Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Verici Dx's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.156	+	0.544)	/	14.305
	=	0.05

Verici Dx's Debt-to-Asset for the quarter that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.159	+	0.462)	/	9.353
	=	0.07

Verici Dx (OTCPK:VRCDF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Verici Dx Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Verici Dx's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx (Verici Dx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

VRCI:UK

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx (Verici Dx) Headlines

No Headlines